Sol-Gel Technologies Ltd.
Business
Sol‑Gel Technologies Ltd. is an innovative dermatology company that researches, develops and commercializes topical prescription therapies. Its main products include approved topical creams Twyneo (for acne vulgaris) and Epsolay (for inflammatory lesions of rosacea) and clinical‑stage candidates SGT‑610 (patidegib gel for Gorlin syndrome) and SGT‑210 (topical erlotinib for Darier and other keratosis disorders). The company’s activities span R&D, clinical development, licensing and commercialization collaborations. It distributes and commercializes products through licensing partners and CMOs across the U.S., Canada, Europe, China/Asia and other selected international markets.
Summary from filing dated 2025-04-29
Financials
Latest annual snapshot (FY2025, period end 2025-12-31). Full statement history unavailable for this entity.
| Revenue | $19.39M |
| Net income | $-6.13M |
| Total assets | $29.92M |
| Total liabilities | $7.11M |
| Stockholders' equity | $22.81M |
| Operating cash flow | $322.0K |